Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Short term Debt (2020 - 2024)

Corbus Pharmaceuticals Holdings has reported Short term Debt over the past 4 years, most recently at $39000.0 for Q4 2023.

  • For Q4 2023, Short term Debt fell 98.6% year-over-year to $39000.0; the TTM value through Dec 2023 reached $39000.0, down 98.6%, while the annual FY2023 figure was $39000.0, 98.6% down from the prior year.
  • Short term Debt for Q4 2023 was $39000.0 at Corbus Pharmaceuticals Holdings, up from $36868.0 in the prior quarter.
  • Over five years, Short term Debt peaked at $9.9 million in Q3 2022 and troughed at $36868.0 in Q2 2023.
  • A 4-year average of $2.1 million and a median of $777000.0 in 2020 define the central range for Short term Debt.
  • Biggest five-year swings in Short term Debt: surged 7691.16% in 2022 and later tumbled 99.63% in 2023.
  • Year by year, Short term Debt stood at $797000.0 in 2020, then skyrocketed by 288.12% to $3.1 million in 2021, then dropped by 9.62% to $2.8 million in 2022, then plummeted by 98.6% to $39000.0 in 2023.
  • Business Quant data shows Short term Debt for CRBP at $39000.0 in Q4 2023, $36868.0 in Q3 2023, and $36868.0 in Q2 2023.